Published Paper Details:

development of effective therapeutic strategies against cancer remains a significant challenge in modern medicine. This study aimed to evaluate the anticancer efficacy of a novel drug molecule on human cancer cell lines in order to assess its potential as a promising treatment option. In this in vitro study, various human cancer cell lines representing different types of cancer were employed, including breast, lung, colon, prostate, and ovarian cancer. The drug molecule under investigation was administered to these cell lines at varying concentrations, and its effects on cell viability, proliferation, and apoptosis were assessed using established experimental protocols. The results demonstrated a dose-dependent inhibition of cell viability in all tested cancer cell lines following treatment with the drug molecule. Additionally, a significant reduction in cell proliferation was observed, indicating the potential of the drug molecule to impede cancer cell growth. Furthermore, the drug molecule induced apoptosis in the cancer cells, as evidenced by morphological changes and activation of apoptotic markers. Notably, the drug molecule exhibited selectivity towards cancer cells, sparing the viability of normal human cells tested in parallel experiments. This selective anticancer activity suggests a potentially favorable therapeutic index, minimizing the risk of adverse effects on healthy tissues. Overall, our findings suggest that the novel drug molecule holds promise as an effective anticancer agent. Further investigations, including in vivo studies and clinical trials, are warranted to validate its efficacy, safety, and clinical applicability. If successful, this drug molecule could contribute significantly to the development of targeted therapies for various types of cancer, improving patient outcomes and survival rates.